10-Q 1 form10q.htm
false Q3 --12-31 false 0001652561 Yes No 0001652561 2023-01-01 2023-09-30 0001652561 2023-09-30 0001652561 2022-12-31 0001652561 2023-07-01 2023-09-30 0001652561 2022-07-01 2022-09-30 0001652561 2022-01-01 2022-09-30 0001652561 us-gaap:CommonStockMember 2022-12-31 0001652561 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001652561 us-gaap:RetainedEarningsMember 2022-12-31 0001652561 us-gaap:NoncontrollingInterestMember 2022-12-31 0001652561 us-gaap:CommonStockMember 2021-12-31 0001652561 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001652561 us-gaap:RetainedEarningsMember 2021-12-31 0001652561 us-gaap:NoncontrollingInterestMember 2021-12-31 0001652561 2021-12-31 0001652561 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001652561 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001652561 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001652561 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001652561 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001652561 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001652561 us-gaap:CommonStockMember 2023-09-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001652561 us-gaap:RetainedEarningsMember 2023-09-30 0001652561 us-gaap:NoncontrollingInterestMember 2023-09-30 0001652561 us-gaap:CommonStockMember 2022-09-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001652561 us-gaap:RetainedEarningsMember 2022-09-30 0001652561 us-gaap:NoncontrollingInterestMember 2022-09-30 0001652561 2022-09-30 0001652561 DQWS:DSwissHoldingLimitedMember country:HK 2023-09-30 0001652561 DQWS:DSwissSdnBhdMember country:MY 2023-09-30 0001652561 country:MY DQWS:DSwissBiotechMember 2023-09-30 0001652561 country:HK DQWS:DSwissBiotechMember 2023-01-17 2023-01-18 0001652561 country:HK DQWS:DSwissBiotechMember 2023-01-18 0001652561 DQWS:DSwissHKLimitedMember 2023-01-18 0001652561 DQWS:DSwissHoldingLimitedMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissHKLimitedMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissSdnBhdMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissBiotechSdnBhdMember 2023-01-01 2023-09-30 0001652561 DQWS:ComputerAndSoftwareMember 2023-09-30 0001652561 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001652561 us-gaap:OfficeEquipmentMember 2023-09-30 0001652561 DQWS:MotorVehiclesMember 2023-09-30 0001652561 DQWS:PeriodEndRMMember 2023-09-30 0001652561 DQWS:PeriodEndRMMember 2022-09-30 0001652561 DQWS:PeriodAverageRMMember 2023-09-30 0001652561 DQWS:PeriodAverageRMMember 2022-09-30 0001652561 DQWS:PeriodEndHKMember 2023-09-30 0001652561 DQWS:PeriodEndHKMember 2022-09-30 0001652561 DQWS:PeriodAverageHKMember 2023-09-30 0001652561 DQWS:PeriodAverageHKMember 2022-09-30 0001652561 DQWS:ManagementServicesAgreementIMember DQWS:DSwissHKLimitedMember 2016-06-26 2016-06-27 0001652561 DQWS:DSwissHKLimitedMember 2023-01-17 2023-01-18 0001652561 DQWS:ComputerAndSoftwareMember 2022-12-31 0001652561 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001652561 us-gaap:OfficeEquipmentMember 2022-12-31 0001652561 DQWS:MotorVehiclesMember 2022-12-31 0001652561 DQWS:FirstFinanceLeaseAgreementMember 2023-01-01 2023-09-30 0001652561 DQWS:SecondFinanceLeaseAgreementMember 2023-01-01 2023-09-30 0001652561 country:US 2023-01-01 2023-09-30 0001652561 country:US 2022-01-01 2022-09-30 0001652561 country:SC 2023-01-01 2023-09-30 0001652561 country:SC 2022-01-01 2022-09-30 0001652561 country:HK 2023-01-01 2023-09-30 0001652561 country:HK 2022-01-01 2022-09-30 0001652561 country:MY 2023-01-01 2023-09-30 0001652561 country:MY 2022-01-01 2022-09-30 0001652561 DQWS:UnitedStatesOfAmericaMember 2023-09-30 0001652561 DQWS:UnitedStatesOfAmericaMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissHKLimitedMember DQWS:HongKongMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissHKLimitedMember DQWS:HongKongMember 2023-09-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember srt:MinimumMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember srt:MaximumMember 2023-01-01 2023-09-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember 2023-09-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2023-07-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2023-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2023-07-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2023-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2023-07-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2023-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerDMember 2023-07-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerDMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerDMember 2023-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerDMember 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerEMember 2023-07-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerEMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerEMember 2023-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerEMember 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomersMember 2023-07-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomersMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomersMember 2023-09-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomersMember 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2022-01-01 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2022-01-01 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2022-01-01 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerDMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerDMember 2022-01-01 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerEMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerEMember 2022-01-01 2022-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomersMember 2023-01-01 2023-09-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomersMember 2022-01-01 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2023-07-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2023-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2023-07-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2023-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2023-07-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2023-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorDMember 2023-07-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorDMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorDMember 2023-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorDMember 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorsMember 2023-07-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorsMember 2022-07-01 2022-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorsMember 2023-09-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorsMember 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2023-01-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2022-01-01 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2023-01-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2022-01-01 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2023-01-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2022-01-01 2022-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorsMember 2023-01-01 2023-09-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorsMember 2022-01-01 2022-09-30 0001652561 us-gaap:AccountingStandardsUpdate201602Member 2022-01-01 0001652561 us-gaap:AccountingStandardsUpdate201602Member 2023-01-01 2023-09-30 0001652561 us-gaap:AccountingStandardsUpdate201602Member 2022-01-01 2022-12-31 0001652561 2022-01-01 2022-12-31 0001652561 DQWS:RelatedPartyAMember 2023-01-01 2023-09-30 0001652561 DQWS:RelatedPartyAMember 2022-01-01 2022-09-30 0001652561 DQWS:RelatedPartyBMember 2023-01-01 2023-09-30 0001652561 DQWS:RelatedPartyBMember 2022-01-01 2022-09-30 0001652561 DQWS:RelatedPartyCMember 2023-01-01 2023-09-30 0001652561 DQWS:RelatedPartyCMember 2022-01-01 2022-09-30 0001652561 DQWS:RelatedPartyAMember 2023-09-30 0001652561 DQWS:NVMember 2023-01-01 2023-09-30 0001652561 DQWS:NVMember 2023-09-30 0001652561 country:SC 2023-09-30 0001652561 country:HK 2023-09-30 0001652561 country:MY 2023-09-30 0001652561 DQWS:NVMember 2022-01-01 2022-09-30 0001652561 DQWS:NVMember 2022-09-30 0001652561 country:SC 2022-09-30 0001652561 country:HK 2022-09-30 0001652561 country:MY 2022-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure DQWS:Integer iso4217:MYR xbrli:shares iso4217:MYR

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended September 30, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________to _______________

 

Commission File Number 333-208083

 

DSwiss, Inc.

(Exact name of registrant issuer as specified in its charter)

 

Nevada   47-4215595
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification No.)

 

Unit 18-11, 18-12 & 18-01, Tower A, Vertical Business Suite,

Avenue 3, Bangsar South, No.8 Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code (603) 2770-4032

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock   DQWS   The OTC Market – Pink Sheets

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES ☒ NO ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

 

YES ☐ NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☐ Smaller reporting company

Emerging growth company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at September 30, 2023
Common Stock, $.0001 par value   206,904,585

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:  
  Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 F-2
  Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months and Nine Months Ended September 30, 2023 and 2022 F-3
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Nine Months Ended September 30, 2023 F-4
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 F-5
  Notes to the Condensed Consolidated Financial Statements F-6 - F-18
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2-5
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 6
ITEM 4. CONTROLS AND PROCEDURES 6
PART II OTHER INFORMATION  
ITEM 1 LEGAL PROCEEDINGS 7
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 7
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 7
ITEM 4 MINE SAFETY DISCLOSURES 7
ITEM 5 OTHER INFORMATION 7
ITEM 6 EXHIBITS 8
SIGNATURES 9

 

 1 
 

 

DSWISS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
Condensed Consolidated Financial Statements  
   
Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 F-2
Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months and Nine Months Ended September 30, 2023 and 2022 F-3
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Nine Months Ended September 30, 2023 F-4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 F-5
Notes to the Condensed Consolidated Financial Statements F-6 - F-18

 

 F-1 
 

 

PART I FINANCIAL INFORMATION

 

Item 1. Unaudited condensed consolidated financial statements:

 

DSWISS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of September 30, 2023 and December 31, 2022

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   September 30, 2023   December 31, 2022 
   Unaudited   Audited 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $288,932   $214,269 
Accounts receivable   37,240    17,492 
Other receivables, prepaid expenses and deposit   19,218    21,749 
Tax recoverable   293    745 
Inventories   8,143    7,483 
Total Current Assets   353,826    261,738 
           
NON-CURRENT ASSETS          
Plant and equipment, net   50,588    72,179 
Intangible assets, net   2,677    3,459 
Operating lease right -of-use, net   10,686    44,548 
Total Non-Current Assets   63,951    120,186 
           
TOTAL ASSETS  $417,777   $381,924 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $102,646   $29,539 
Other payables and accrued liabilities   169,281    154,710 
Finance lease liability   3,945    16,515 
Operating lease liability   10,686    44,548 
Total Current Liabilities   286,558    245,312 
           
NON- CURRENT LIABILITIES          
Finance lease liability   36,170    38,461 
Total non-current liabilities   36,170    38,461 
           
TOTAL LIABILITIES  $322,728   $283,773 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.0001 par value, 200,000,000 shares authorized, None issued and outstanding   -    - 
Common stock, $0.0001 par value, 600,000,000 shares authorized, 206,904,585 shares issued and outstanding as of September 30, 2023 and December 31, 2022 respectively  $20,690   $20,690 
Additional paid-in capital   1,395,426    1,395,426 
Accumulated other comprehensive income/(loss)   23,481    (5,846)
Accumulated deficit   (1,344,548)   (1,324,002)
           
TOTAL DSWISS, INC. STOCKHOLDERS’ EQUITY  $95,049   $86,268 
NON-CONTROLLING INTEREST   -    11,883 
TOTAL STOCKHOLDERS’ EQUITY   95,049    98,151 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $417,777   $381,924 

 

See accompanying notes to condensed consolidated financial statements.

 

 F-2 
 

 

DSWISS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(Unaudited)

 

   2023   2022   2023   2022 
   Three months ended
September 30
   Nine months ended
September 30
 
   2023   2022   2023   2022 
   $   $   $   $ 
REVENUE   425,569    426,591    1,046,764    1,613,823 
                     
COST OF REVENUE   (281,010)   (193,969)   (728,508)   (1,189,356)
                     
GROSS PROFIT   144,559    232,622    318,256    424,467 
                     
OTHER INCOME   1,384    -    4,462    3,410 
                     
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES   (89,202)   (97,457)   (270,260)   (251,716)
                     
OPERATING EXPENSES   (258)   (257)   (1,052)   (1,045)
                     
FINANCE COST   (622)   (1,377 )    (2,490)   (5,021)
                     
LEASE EXPENSES   (10,703)   (10,381)   (32,349)   (31,818)
                     
PROFIT BEFORE INCOME TAX   45,158    123,150    16,567    138,277 
                     
TAXATION   (162)   (349)   (497)   (349)
                     
NET PROFIT   44,996    122,801    16,070    137,928 
Non-Controlling Interest   -    5,112    -    10,036 
Other comprehensive (loss)/income                    
- Foreign currency translation adjustment   (2,525)   (10,430)   29,327    (15,454)
                     
TOTAL COMPREHENSIVE INCOME   42,471    117,483    45,397    132,510 
                     
NET INCOME PER SHARE – BASIC AND DILUTED   0.0002    0.0006    0.0002    0.0006 
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED   206,904,585    206,904,585    206,904,585    206,904,585 

 

See accompanying notes to condensed consolidated financial statements.

 

 F-3 
 

 

DSWISS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”))

(unaudited)

 

Nine Months Ended September 30, 2023 (Unaudited)

 

   

Number of

shares

    Amount    

PAID-IN

CAPITAL

   

COMPREHENSIVE
INCOME/(LOSS)

   

ACCUMULATED

DEFICIT

   

CONTROLLING

INTEREST

   

TOTAL

EQUITY

 
    COMMON STOCK     ADDITIONAL    

ACCUMULATED
OTHER

          NON-        
   

Number of

shares

    Amount    

PAID-IN

CAPITAL

   

COMPREHENSIVE
INCOME/(LOSS)

   

ACCUMULATED

DEFICIT

   

CONTROLLING

INTEREST

   

TOTAL

EQUITY

 
Balance as of December 31, 2022 (audited)     206,904,585       20,690       1,395,426       (5,846 )     (1,324,002 )     11,883       98,151  
Foreign currency translation adjustment     -       -       -       29,327       -         -     29,327  
Changes in ownership interests in an associate     -       -       -       -       (36,616 )     (11,883 )     (48,499 )
Net profit     -       -       -       -       16,070       -       16,070  
Balance as of September 30, 2023 (unaudited)     206,904,585       20,690       1,395,426       23,481       (1,344,548 )     -       95,049  

 

Nine Months Ended September 30, 2022 (Unaudited)

 

   COMMON STOCK   ADDITIONAL   ACCUMULATED
OTHER
       NON-     
   Number of shares   Amount   PAID-IN
CAPITAL
   COMPREHENSIVE
LOSS
   ACCUMULATED
DEFICIT
   CONTROLLING
INTEREST
  

TOTAL

EQUITY

 
Balance as of December 31, 2021 (audited)   206,904,585    20,690    1,395,426    (32,985)   (1,309,711)   589    74,009 
Foreign currency translation adjustment   -    -    -    (15,454)   -    574    (14,880)
Net profit/(loss)   -    -    -    -    147,964    (10,036)   137,928 
Balance as of September 30, 2022 (unaudited)   206,904,585    20,690    1,395,426    (48,439)   (1,161,747)   (8,873)   197,057 

 

See accompanying notes to condensed consolidated financial statements.

 

 F-4 
 

 

DSWISS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(Unaudited)

 

    2023     2022  
    Nine months ended September 30,  
    2023     2022  
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net profit before income tax   $ 16,567     $ 138,277  
Adjustments to reconcile net profit to net cash generated from operating activities:                
Depreciation and amortization     50,650       54,674  
Amortization for intangible assets     772       772  
Changes in operating assets and liabilities:                
Accounts payable     30,140       12,064  
Accounts receivable     23,937       (47,955 )
Other payables and accrued liabilities     20,476       (115,925 )
Inventories     (1,105 )     6,352  
Other receivables, prepaid expenses and deposits     1,235       24,469  
Lease liabilities     (31,209 )     (29,930 )
Amount due to director     -       (36,439 )
Cash generated from operations     111,463       6,359  
Tax paid     (74 )     (491 )
Net cash generated from operating activities     111,389       5,868  
                 
CASH FLOWS FROM INVESTING ACTIVITY:                
Purchase of plant and equipment     (364 )     (8,220 )
Net cash used in investing activity     (364 )     (8,220 )
                 
CASH FLOWS FROM FINANCING ACTIVITY:                
Repayment of finance lease     (11,586 )     (11,091 )
Net cash used in financing activity     (11,586 )     (11,091 )
                 
Effect of exchange rate changes on cash and cash equivalent     (24,776 )     (30,687 )
                 
Net increase/(decrease) in cash and cash equivalents     74,663       (44,130 )
Cash and cash equivalents, beginning of period     214,269       234,546  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 288,932     $ 190,416  
SUPPLEMENTAL CASH FLOWS INFORMATION                
Income taxes paid   $ (74 )   $ (491 )
Interest paid   $ (410 )   $ (425 )

 

See accompanying notes to condensed consolidated financial statements.

 

 F-5 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

1. DESCRIPTION OF BUSINESS AND ORGANIZATION

 

DSwiss, Inc. is organized as a Nevada limited liability company, incorporated on May 28, 2015. For the purposes of financial statement presentation, DSwiss, Inc. and its subsidiaries are herein referred to as “the Company” or “we”. The principal activity of the Company is premier biotech-nutraceutical, beauty supplies, and medical consumables supplies. The Company sells medical consumable supplies, food supplements, skincare, and other related beauty products in Malaysia and around the ASEAN region. We are globally recognized Turnkey Private Label Manufacturing Services for nutraceutical and skincare OEM/ODM products.

 

Our professionals manage from custom formulation of scientifically proven and naturally effective, sourcing raw materials, production, quality control, stability, and safety test, clinical testing by third-party labs, packaging, and shipping, including import and export.

 

Our manufacturing facilities which compliant with GMP (Good Manufacturing Practise), FDA (Food Drug Association), HACCP (Hazard Analysis and Critical Control Point), JAKIM HALAL, and Mesti.

 

The accompanying unaudited condensed consolidated financial statements of DSwiss, Inc. at September 30, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended December 31, 2022. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the periods ended September 30, 2023 and 2022 presented are not necessarily indicative of the results to be expected for the full year. The December 31, 2022 balance sheet has been derived from our audited financial statements included in our annual report on Form 10-K for the year ended December 31, 2022.

 

We have historically conducted our business through DSwiss Sdn Bhd, a private limited liability company, incorporated in Malaysia. DSwiss Holding Limited, incorporated in Seychelles, is an investment holding company with 100% equity interest in DSwiss (HK) Limited, a company incorporated in Hong Kong, which subsequent hold 100% equity interest in DSwiss Sdn. Bhd. On August 31, 2015, DSwiss, Inc. was restructured to be the holding company parent to, and succeed to the operations of, DSwiss Holding Limited. The former unit holder of DSwiss Holding Limited became the unit holder of DSwiss, Inc. and DSwiss Holding Limited became a wholly-owned subsidiary of DSwiss, Inc. This transaction was accounted for as a transaction among entities under common control and the assets, liabilities, revenues and expenses of DSwiss Holding Limited were carried over to and combined with DSwiss, Inc. at historical cost, and as if the transfer occurred at the beginning of the period. Prior periods have been retrospectively adjusted for comparative purposes.

 

We have invested in DSwiss Biotech Sdn Bhd, a Company incorporated in Malaysia, and owned 40% equity interest. On January 18, 2023, DSwiss (HK) Limited acquired 150,000 shares, representing 60% equity interest in DSwiss Biotech Sdn. Bhd., from the other party with consideration of RM 1. After such acquisition, DSwiss Biotech Sdn. Bhd. became a wholly owned subsidiary of DSwiss (HK) Limited.

 

The Company, through its subsidiaries, mainly supplies high quality beauty products. Details of the Company’s subsidiaries:

 

   Company name  Place and date
of incorporation
  Particulars of issued
capital
  Principal activities  Proportional
of ownership interest
and voting power
held
 
                 
1.  DSwiss Holding Limited  Seychelles, May 28, 2015  1 share of ordinary share of US$1 each  Investment holding   100%
                  
2.  DSwiss (HK) Limited  Hong Kong, May 28, 2015  1 share of ordinary share of HK$1 each  Supply of beauty products   100%
                  
3.  DSwiss Sdn Bhd  Malaysia, March 10, 2011  2 shares of ordinary share of RM 1 each  Supply of beauty products   100%
                  
4.  DSwiss Biotech Sdn Bhd  Malaysia, March 17, 2016  250,000 shares of ordinary share of RM 1 each  Supply of biotech products   100%

 

 F-6 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the period ended September 30, 2023, the Company suffered an accumulated deficit of $1,344,548. This factor raises substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The Company’s ability to continue as a going concern is dependent upon improving its profitability and the continuing financial support from its shareholders. Management believes the existing shareholders or external financing will provide the additional cash to meet the Company’s obligations as they become due. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, if needed, it may contain undue restrictions on its operations, in the case of debt financing, or cause substantial dilution for its stock holders, in the case of equity financing.

 

Basis of presentation

 

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

 

Basis of consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its subsidiaries in which the Company is the primary beneficiary. All inter-company accounts and transactions have been eliminated upon consolidation.

 

Use of estimates

 

In preparing these consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets, and revenues and expenses during the periods reported. Actual results may differ from these estimates.

 

Revenue recognition

 

The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

 

Revenue from trading of retail goods is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The Company mainly derives its revenue from the sale of healthy food products. Generally, the Company recognizes revenue when OEM, Home brand and medical consumables product are sold and accepted by the customers and there are no continuing obligations to the customer.

 

Cost of revenue

 

Cost of revenue includes the purchase cost of retail goods for re-sale to customers and packing materials (such as boxes). It excludes purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs and other costs of distribution network in cost of revenues.

 

 F-7 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

Selling and distribution expenses

 

Selling and distribution expenses are primarily comprised of travelling and accommodation, transportation fees such as petrol, toll and parking and shipping and handling fees.

 

Cash and cash equivalents

 

The Company consider all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalent.

 

Inventories

 

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

Plant and equipment

 

Plant and equipment are stated at cost less accumulated depreciation and impairment. Depreciation of plant, equipment and software are calculated on the straight-line method over their estimated useful lives or lease terms generally as follows:

 

Classification   Estimated useful lives
Computer and software   5 years
Furniture and fittings   5 years
Office equipment   10 years
Motor vehicle   5 years

 

Intangible assets

 

Intangible assets are stated at cost less accumulated amortization. Intangible assets represented the registration costs of trademarks in Malaysia and Hong Kong, which are amortized on a straight-line basis over a useful life of ten years.

 

The Company follows ASC Topic 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. There were no impairment losses recorded on intangible assets for the nine months ended September 30, 2023.

 

Leases

 

Prior to November 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective November 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The implementation of ASC 842 did not have a material impact on the Company’s consolidated financial statements and did not have a significant impact on our liquidity. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods (see Note 10).

 

Income taxes

 

The provision of income taxes is determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

 

The Company conducts much of its businesses activities in Hong Kong and is subject to tax in this jurisdiction. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

 F-8 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

Net income/(loss) per share

 

The Company calculates net income/(loss) per share in accordance with ASC Topic 260, “Earnings per Share.” Basic income/(loss) per share is computed by dividing the net income/(loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed similar to basic income/(loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

 

Foreign currencies translation

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the Company’s subsidiaries and VIEs in Malaysia and Hong Kong maintains their books and record in their local currency, Ringgits Malaysia (“RM”) and Hong Kong Dollars (“HK$”) respectively, which is functional currency as being the primary currency of the economic environment in which the entity operates.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity.

 

Translation of amounts from RM into US$1 and HK$ into US$1 has been made at the following exchange rates for the respective periods:

 

   

As of and for the

nine months ended

September 30,

 
    2023     2022  
             
Period-end RM : US$1 exchange rate     4.70       4.64  
Period-average RM : US$1 exchange rate     4.53       4.36  
Period-end HK$ : US$1 exchange rate     7.83       7.85  
Period-average HK$ : US$1 exchange rate     7.84       7.84  

 

 F-9 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments:

 

The carrying value of the Company’s financial instruments: cash and cash equivalents, accounts receivable, deposits, accounts payable, other payables, and accounts payable approximate at their fair values because of the short-term nature of these financial instruments.

 

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

Level 1: Observable inputs such as quoted prices in active markets;

 

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

Segment reporting

 

ASC Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. For the six months ended June 30, 2023, the Company operates in three reportable operating segments in Malaysia and Hong Kong.

 

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topics 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. In November 2019, the FASB issued ASU 2019-10 highlighted the adoption timeline. For smaller reporting entities, Topic 326 is effective for annual periods beginning after December 15, 2022, including interim period within those fiscal years, of which is effective for the Company on January 1, 2023 as the Company is qualified as a smaller reporting company. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

 

Credit loss rate is determined by historical collection based on aging schedule, adjusted for current conditions using reasonable and supportable forecast. Based on the aging categorization and the adjusted loss per category, an allowance for credit losses is calculated by multiplying the adjusted loss rate with the amortized cost in the respective age category.

 

Recently Issued Accounting Standard

 

The Company reviews new accounting standards as issued. Management has not identified any other new standards that is believes will have a significant impact on the Company’s financial statements.

 

 F-10 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

3. VIE STRUCTURE AND ARRANGEMENTS

 

On June 27, 2016, DSwiss (HK) Limited (“DSHK”) entered into a Management Services Agreement (the “Management Services Agreement I”) which entitles DSHK to substantially entitled to all of the economic benefits of DSwiss Biotech Sdn Bhd (“DSBT”) in consideration of services provided by DSHK to DSBT. Pursuant to the Management Services Agreement I, DSHK has the exclusive right to provide to DSBT management, financial and other services related to the operation of DSBT’s business, and DSBT is required to take all commercially reasonable efforts to permit and facilitate the provision of the services provided by DSHK. As compensation for providing the services, DSHK is entitled to receive a fee from DSBT, upon demand, equal to 100% of the annual net profits of DSBT during the term of the Management Services Agreement I. DSHK may also request, on ad hoc basis, quarterly payments of the aggregate fee, which payments will be credited against DSBT’s future payment obligations.

 

The Management Services Agreement I also provides DSHK, or its designee, with a right of first refusal to acquire all or any portion of the equity of DSBT upon any proposal by the sole shareholder of DSBT to transfer such equity. In addition, at the sole discretion of DSHK, DSBT is obligated to transfer to DSHK, or its designee, any part or all of the business, personnel, assets and operations of DSBT which may be lawfully conducted, employed, owned or operated by DSHK, including:

 

(a) business opportunities presented to, or available to DSBT may be pursued and contracted for in the name of DSHK rather than DSBT, and at its discretion, DSHK may employ the resources of DSBT to secure such opportunities;

 

(b) any tangible or intangible property of DSBT, any contractual rights, any personnel, and any other items or things of value held by DSBT may be transferred to DSHK at book value;

 

(c) real property, personal or intangible property, personnel, services, equipment, supplies and any other items useful for the conduct of the business may be obtained by DSHK by acquisition, lease, license or otherwise, and made available to DSBT on terms to be determined by agreement between DSHK and DSBT;

 

(d) contracts entered into in the name of DSBT may be transferred to DSHK, or the work under such contracts may be subcontracted, in whole or in part, to DSHK, on terms to be determined by agreement between DSHK and DSBT; and

 

(e) any changes to, or any expansion or contraction of, the business may be carried out in the exercise of the sole discretion of DSHK, and in the name of and at the expense of, DSHK; provided, however, that none of the foregoing may cause or have the effect of terminating (without being substantially replaced under the name of DSHK) or adversely affecting any license, permit or regulatory status of DSBT.

 

In addition, DSHK entered into certain agreements with Jervey Choon, (the “DSBT shareholder”), including

 

(i) a Call Option Agreement allowing DSHK to acquire the shares of DSBT as permitted by Malaysia laws;
   
(ii) a Shareholders’ Voting Rights Proxy Agreement that provides DSHK with the voting rights of the DSBT; and
   
(ii) an Equity Pledge Agreement that pledges the shares in DSBT.

 

This VIE structure provides DSHK, a wholly-owned subsidiary of DSwiss Holding Limited, which is the wholly-owned subsidiary of DSwiss Inc, with control over the operations and benefits of DSBT without having a direct equity ownership in DSBT.

 

On January 18, 2023, DSwiss (HK) Limited acquired 150,000 shares, representing 60% equity interest in DSwiss Biotech Sdn. Bhd., from the other party with consideration of RM 1. After such acquisition, DSwiss Biotech Sdn. Bhd. became a wholly owned subsidiary of DSwiss (HK) Limited.

 

 F-11 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

4. STOCKHOLDERS’ EQUITY

 

As of September 30, 2023, the Company had a total of 206,904,585 of its common stock issued and outstanding. There are no shares of preferred stock issued and outstanding.

 

5. PLANT AND EQUIPMENT

 

   September 30, 2023   December 31, 2022 
Computer and software  $105,535   $105,535 
Furniture and fittings   6,144    6,144 
Office equipment   21,516    21,152 
Motor vehicle   135,868    135,868 
Total plant and equipment  $269,063   $268,699 
Accumulated depreciation   (205,538)   (187,236)
Effect of translation exchange   (12,937)   (9,284)
Plant and equipment, net  $50,588   $72,179 

 

Depreciation expense for the three months and nine months ended September 30, 2023 were $3,926 and $18,302 respectively.

 

Depreciation expense for the three months and nine months ended September 30, 2022 were $7,164 and $22,856 respectively.

 

6. INTANGIBLE ASSETS

 

   September 30, 2023   December 31, 2022 
Trademarks  $12,077   $12,077 
Amortization   (8,936)   (8,164)
Effect of translation exchange   (464)   (454)
Intangible assets, net  $2,677   $3,459 

 

Amortization for the three months and nine months ended September 30, 2023 was $258 and $772 respectively.

 

Amortization for the three months and nine months ended September 30, 2022 was $257 and $772 respectively.

 

7. OTHER RECEIVABLES, PREPAID EXPENSES AND DEPOSITS

 

   September 30, 2023   December 31, 2022 
Other receivables  $66   $- 
Prepaid expenses   655    2,080 
Deposits   18,497    19,669 
Total prepaid expenses and deposits  $19,218   $21,749 

 

8. INVENTORIES

 

   September 30, 2023   December 31, 2022 
Finished goods, at cost  $8,143   $7,483 
Total inventories  $8,143   $7,483 

 

9. OTHER PAYABLES AND ACCRUED LIABILITIES

 

   September 30, 2023   December 31, 2022 
Other payables  $104,755   $100,385 
Accrued audit fees   36,862    20,266 
Accrued other expenses   13,383    16,683 
Accrued professional fees   14,281    17,376 
Total payables and accrued liabilities  $169,281   $154,710 

 

 F-12 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

10. FINANCE LEASE LIABILITY

 

The Company purchased motor vehicles with finance lease. The first finance lease agreement commenced on July 31, 2018 with the effective interest rate of 3.62% per annum, due through June, 2025, with principal and interest payable monthly. The second finance lease agreement commenced on December 3, 2021 with the effective interest rate of 3.70% per annum, due through November, 2026, with principal and interest payable monthly. The obligation under the finance lease is as follows:

 

   As of
September 30, 2023
   As of
December 31, 2022
 
Finance lease  $42,273   $58,768 
Less: interest expense   (2,158)   (3,792)
Net present value of finance lease   40,115    54,976 
           
Current portion   3,945    16,515 
Non-current portion   36,170    38,461 
Total  $40,115   $54,976 

 

As of September 30, 2023 the maturities of the finance lease for each of the years are as follows:

 

      
2023   3,945 
2024   16,197 
2025   12,369 
2026   7,604 
Total  $40,115 

 

 F-13 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

11. INCOME TAXES

 

For the nine months ended September 30, 2023 and 2022, the local (United States) and foreign components of profit before income taxes were comprised of the following:

 

   For the nine
months ended
September 30, 2023
   For the nine
months ended
September 30, 2022
 
         
Tax jurisdictions from:          
- Local  $(53,487)  $(30,867)
- Foreign, representing          
Seychelles   (6,454)   (2,543)
Hong Kong   (4,816)   (3,055)
Malaysia   81,324    174,742 
           
Profit before income tax  $16,567   $138,277 

 

The provision for income taxes consisted of the following:

 

   For the nine
months ended
September 30, 2023
   For the nine
months ended
September 30, 2022
 
Current:          
- Local  $-   $- 
- Foreign   (497)   (349)
           
Deferred:          
- Local   -    - 
- Foreign   -    - 
           
Income tax expense  $(497)  $(349)

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company has subsidiaries that operate in various countries: United States, Seychelles, Hong Kong and Malaysia that are subject to taxes in the jurisdictions in which they operate, as follows:

 

United States of America

 

The Company is registered in the State of Nevada and is subject to the tax laws of the United States of America. As of September 30, 2023, the operations in the United States of America incurred $525,638 of cumulative net operating losses which can be carried forward to offset future taxable income, at the tax rate of 21%. The net operating loss carry forwards begin to expire in 2038, if unutilized. The Company has provided for a full valuation allowance of $110,384 against the deferred tax assets on the expected future tax benefits from the net operating loss carry forwards as the management believes it is more likely than not that these assets will not be realized in the future.

 

Seychelles

 

Under the current laws of the Seychelles, DSwiss Holding Limited is registered as an international business company which governs by the International Business Companies Act of Seychelles and there is no income tax charged in Seychelles.

 

Hong Kong

 

DSwiss (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income tax rate of 16.5% on its assessable income. As of September 30, 2023, the operations in the Hong Kong incurred $635,919 of cumulative net operating losses which can be carried forward to offset future taxable income, at the tax rate of 16.5%. The Company has provided for a full valuation allowance of $104,927 against the deferred tax assets on the expected future tax benefits from the net operating loss carry forwards as the management believes it is more likely than not that these assets will not be realized in the future.

 

Malaysia

 

DSwiss Sdn. Bhd. and DSwiss Biotech Sdn. Bhd. are subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range from 15% to 24% on its assessable income. As of September 30, 2023, the operations in the Malaysia incurred $136,141 of cumulative net operating losses which can be carried forward to offset future taxable income, at the tax rate of 15%. The Company has provided for a full valuation allowance of $20,421 against the deferred tax assets on the expected future tax benefits from the net operating loss carry forwards as the management believes it is more likely than not that these assets will not be realized in the future.

 

 F-14 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

12. CONCENTRATIONS OF RISK

 

The Company is exposed to the following concentrations of risk:

 

(a) Major customers

 

For three months ended September 30, 2023 and 2022, the customers who accounted for 10% or more of the Company’s revenues and its accounts receivable balance at period-end are presented as follows:

 

   2023   2022   2023   2022   2023   2022 
   Revenue   Percentage of revenue   Accounts receivable 
                         
Customer A  $62,284   $-    14%   -%  $-   $- 
Customer B  $-   $96,968    -%   22%  $-   $- 
Customer C  $74,508   $105,004    17%   23%  $15,335   $40,729 
Customer D  $98,487   $55,323    23%   12%  $16,613   $- 
Customer E  $142,344   $-    33%   -%  $-   $- 
   $377,623   $257,295    87%   57%  $31,948   $40,729 

 

For nine months ended September 30, 2023 and 2022, the customers who accounted for 10% or more of the Company’s revenues and its accounts receivable balance at period-end are presented as follows:

 

   2023   2022   2023   2022   2023   2022 
   Revenues   Percentage of revenues   Accounts receivable, trade 
                         
Customer A  $125,478   $-    12%   -%  $-   $- 
Customer B  $-   $506,241    -%   31%  $-   $- 
Customer C  $200,283   $355,854    19%   22%  $15,335   $40,729 
Customer D  $197,831   $165,491    19%   10%  $16,613   $- 
Customer E  $288,649   $-    28%   -%  $-   $- 
   $812,241   $1,027,586    78%   63%  $31,948   $40,729 

 

(b) Major vendors

 

For three months ended September 30, 2023 and 2022, the vendors who accounted for 10% or more of the Company’s purchases and its accounts payable balance at period-end are presented as follows:

 

   2023   2022   2023   2022   2023   2022 
   Purchase   Percentage of purchase   Accounts payable 
                         
Vendor A  $45,004   $44,229    17%   22%  $10,303   $3,910 
Vendor B  $147,361   $71,890    56%   35%  $54,633   $- 
Vendor C  $-   $24,337    -%   12%  $15,761   $14,981 
Vendor D  $-   $28,449    -%   14%  $-   $- 
   $192,365   $168,905    73%   83%  $80,697   $18,891 

 

For nine months ended September 30, 2023 and 2022, the vendors who accounted for 10% or more of the Company’s purchases and its accounts payable balance at period-end are presented as follows:

 

   2023   2022   2023   2022   2023   2022 
   Purchase   Percentage of purchases   Accounts payable, trade 
                         
Vendor A  $119,092   $444,392    16%   38%  $10,303   $3,910 
Vendor B  $311,832   $255,687    43%   22%  $54,633   $- 
Vendor C  $118,417   $182,350    16%   15%  $15,761   $14,981 
   $549,341   $882,429    75%   75%  $80,697   $18,891 

 

All vendors are located in Malaysia.

 

(c) Credit risk

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its accounts receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

(d) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain stable, therefore there is a possibility that the Company could post the same amount of income for two comparable periods and because of the fluctuating exchange rate actually post higher or lower income depending on exchange rate of RM converted to US$ and HK$ converted into US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

 F-15 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

13. LEASE RIGHT-OF-USE ASSET AND LEASE LIABILITIES

 

The Company officially adopted ASC 842 for the period on and after January 1, 2019 as permitted by ASU 2016-02. ASC 842 originally required all entities to use a “modified retrospective” transition approach that is intended to maximize comparability and be less complex than a full retrospective approach. On July 30, 2018, the FASB issued ASU 2018-11 to provide entities with relief from the costs of implementing certain aspects of the new leasing standard, ASU 2016-02 of which permits entities may elect not to recast the comparative periods presented when transitioning to ASC 842. As permitted by ASU 2018-11, the Company elect not to recast comparative periods, thusly.

 

As of January 1, 2022, the Company recognized approximately US$92,606, lease liability as well as right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. Lease liabilities are measured at present value of the sum of remaining rental payments as of January 1, 2022, with discounted rate of 5.4% adopted from Public Bank Berhad’s base lending rate as a reference for discount rate.

 

A single lease cost is recognized over the lease term on a generally straight-line basis. All cash payments of operating lease cost are classified within operating activities in the statement of cash flows.

 

The operating lease right and lease liability as follow:

 

As of September 30, 2023 and December 31, 2022, operating lease right of use asset as follow:

 

   As of
September 30, 2023
   As of
December 31, 2022
 
As of beginning of the period/year  $44,548   $92,606 
Accumulated amortization   (32,349)   (42,310)
Effect of translation exchange   (1,513)   (5,748)
Balance as of end of the period/year  $10,686   $44,548 

 

As of September 30, 2023 and December 31, 2022, the amortization of the operating lease right of use asset are $32,349 and $42,310 respectively.

 

 F-16 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

As of September 30, 2023, operating lease liability as follow:

 

As of January 1, 2023  $44,548 
Less: gross repayment   (33,379)
Add: imputed interest   1,030 
Effect of translation exchange   (1,513)
Balance as of September 30, 2023  $10,686 
Less: lease liability current portion   (10,686)
Lease liability non-current portion  $- 

 

Maturities of operating lease obligation as follow:

 

Year ending     
December 31, 2023   10,686 
Total  $10,686 

 

Other information:

 

   As of
September 30, 2023
   As of
December 31, 2022
 
   (unaudited)   (audited) 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flow from operating lease  $31,209   $42,212 
Right-of-use assets obtained in exchange for operating lease liabilities   10,686    44,548 
Remaining lease term for operating lease (years)   0.25    1 
Weighted average discount rate for operating lease   5.4%   5.4%

 

As of September 30, 2023 and December 31, 2022, lease expenses were $32,349 and $42,310 respectively.

 

14. RELATED PARTY TRANSACTIONS

 

For the period ended September 30, 2023 the Company has the following transactions with related party:

 

   For the period ended
September 30, 2023
   For the period ended
September 30, 2022
 
   (Unaudited)   (Unaudited) 
Professional Fees:          
- Related party A  $6,700   $6,700 
           
Sales          
- Related party B  $200,283   $355,854 
- Related party C   46,700    4,478 
           
Total  $253,683   $367,032 

 

The related party A, is a wholly owned subsidiary of a 7.33% shareholder of the Company.

 

The related party B’s director and shareholder is the founder of the Company. Founder of the Company resigned as director of company B on October 02, 2022 and is no longer a shareholder of company B.

 

The related party C’s director and shareholder is the founder of the Company.

 

The related party transaction is generally transacted in an arm-length basis at the current market value in the normal course of business.

 

15. SEGMENTED INFORMATION

 

ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services categories, business segments and major customers in financial statements. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.

 

 F-17 
 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

The Company had no inter-segment sales for the periods presented. Summarized financial information concerning the Company’s reportable segments is shown as below:

 

By Geography*:

 

   Nevada*   Seychelles*   Hong Kong*   Malaysia*   Total* 
   For the period ended September 30, 2023 
   Nevada   Seychelles   Hong Kong   Malaysia   Total 
                     
Revenue  $-   $-   $-   $1,046,764   $1,046,764 
Cost of revenue   -    -    -    (728,508)   (728,508)
Depreciation and amortization   -    -    (772)   (50,650)   (51,422)
Net (loss)/profit before taxation   (53,487)   (6,454)   (4,816)   81,324    16,567 
                          
Total assets  $11,522   $19,098   $11,305   $375,852   $417,777 

 

   Nevada*   Seychelles*   Hong Kong*   Malaysia*   Total* 
   For the period ended September 30, 2022 
   Nevada   Seychelles   Hong Kong   Malaysia   Total 
                     
Revenue  $-   $-   $-   $1,613,823   $1,613,823 
Cost of revenue   -    -    -    (1,189,356)   (1,189,356)
Depreciation and amortization   -    -    (772)   (54,674)   (55,446)
Net (loss)/profit before taxation   (30,867)   (2,543)   (3,055)   174,742    138,277 
                          
Total assets  $27,186   $7,056   $14,448   $351,821   $400,511 

 

* Revenues and costs are attributed to countries based on the location of customers.

 

16. SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after September 30, 2023 up through the date the Company issued the consolidated financial statements.

 

 F-18 
 

 

Item 2. Management’s discussion and analysis of financial condition and results of operations

 

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended December 31, 2022 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in our Form S-1 Amendment No.8, dated July 20, 2016 in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited Condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

DSwiss, Inc., a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on May 28, 2015. DSwiss Holding Limited owns 100% of DSwiss (HK) Limited, a Hong Kong Company, which owns 100% of DSwiss Sdn Bhd, the operating Malaysia Company of which is described below. In 2016, DSwiss (HK) Limited invested in DSwiss Biotech Sdn Bhd, incorporated in Malaysia, and owned 40% equity interest.

 

DSwiss is the leading corporation for premier nutraceutical biotechnology in USA, and has gone into Asian countries such as China, Hong Kong, Singapore, Thailand, and Malaysia with our high quality functional health supplement, skin care solution, wellness products and private labelled supplies turnkey provider (OEM/ODM). Our unique and innovative patented biotechnology, natural ingredients into products & services that has been proven to give better, faster and visible positive results to the end user including health improvement, slimming, anti-aging and beauty effects.

 

Currently, we are fulfilling in Talent Development, product research and development, and providing Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services into functional food and beauty product of which is currently under research and development with Malaysia biotech and research professionals. Our professionals manage from custom formulation of scientifically-proven and naturally-effective, sourcing raw materials, production, quality control, stability and safety test, clinical testing by third-party labs, packaging and shipping including import and export, all licenses needed so customer can concentrate on what they should do. In 2020, with our experience and expertise, we have successfully expanded our client base in OEM/ODM services and developed products and Business-to-business (B2B) DNA genotyping private label services that exceed the clients’ expectation.

 

DSwiss has continuously expanding through launching health and beauty projects to provide premier experiences to the customers. DSwiss has shown a solid growth and is set to advance the biotechnology industry to drive nutraceutical and skincare biotechnology growth.

 

At this time, we operate exclusively online through our website: http://www.dswissbeauty.com.

 

Products which meet the definition of a functional food and cosmetics related products need to be registered or notified with the Drug Control Authority (DCA), Ministry of Health Malaysia. Manufacturing, marketing, importation and the sale of unregistered products is a violation of the Drug Control Regulations and Cosmetics Act 1984 of Malaysia and enforcement action can be taken.

 

At DSwiss, research and development is an ongoing effort whose purpose is to ensure our products on the forefront of quality and effectiveness. Equipped with state of the art machinery, our innovative research and development team are constantly exploring on new development and product lines that will enable us to provide the highest quality standard and remain competitive in the industry.

 

DSwiss’s products are certified and approved by the Ministry of Health (“MOH”) Malaysia. Due to the stringent requirements from MOH Malaysia, we strive to upkeep the highest possible standard in our products to provide assurance and as a prove of our continuing commitment to providing quality products.

 

Our expected growth is planned to occur primarily through the implementation of our social media marketing strategy. DSwiss already has a strong relationship with new retail tech company (eg. Facebook, E-Marketplace). The global presence social media has helped provide to us has been an invaluable resource, and as we continue to expand our business operations and spread our brand awareness, we intend to primarily utilize social media to reach our customers. The benefits of social media are countless, but perhaps the most imperative to our future success is our ability to connect with customers directly, to receive their feedback almost instantaneously. On that note, the feedback we have received from our clients has been overwhelmingly positive, which has helped us to create a robust brand image.

 

While DSwiss has been focused almost exclusively upon pursuing operations within Asia, we do have plans to expand outward and become a household name across the world. Our strategy to do so going forward is by forming partnerships with local companies in various countries that may be willing to stock our products or promote them to their own customers. We believe that by forging strategic relationships and partnerships we can expand our operations across the globe at a greater pace and with greater certainty than we would if we tried to expand on our own.

 

Results of Operation

 

For the Three Months and Nine Months Ended September 30, 2023 and September 30, 2022.

 

For the three and nine months ended September 30, 2023, we realized revenue in the amount of $425,569 and $1,046,764, while for the three and nine months ended September 30, 2022, we realized revenues in the amount of $426,591 and $1,613,823. Our gross profits for the three and nine months ended September 30, 2023 were $144,559 and $318,256, which is less than $88,063 and $106,211 for the three months ended September 30, 2022 and for the nine months ended September 30, 2022. We believe that in order to retain and maintain more customers in the future we must increase our marketing efforts and or develop new products.

 

 2 
 

 

*Our gross margins may not be comparable to those of other entities, since some entities include all the costs related to their distribution network in cost of revenue. Our cost of revenue includes only the purchase cost of products and packing materials, and does not include any allocation of inbound freight charges, purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs, and the other costs associated with the distribution network.

 

Our net profit for the three and nine months ended September 30, 2023 were $44,996 and $16,070 respectively, while the net profit for the three and nine months ended September 30, 2022 were $122,801 and $137,928.

 

Liquidity and Capital Resources

 

For the nine months ended September 30, 2023 and 2022, we had cash and cash equivalents of $288,932 and $190,416 respectively. We have negative operating cash flow and we need to meet our working capital requirements to make capital investments in connection with ongoing operations. The Company expects its current capital resources to meet our basic operating requirements for approximately twelve months.

 

Operating Activities

 

For the nine months ended September 30, 2023, net cash generated from operating activities was $111,389, compared to net cash generated from operating activities was $5,868 in the prior period. The operating cash flow performance primarily reflects increase in accounts payable, other payables and accrued liabilities to the prior period.

 

Investing Activities

 

For the nine months ended September 30, 2023 and 2022, net cash used in investing activities were $364 and $8,220 respectively, reflecting the cost in purchase of plant and equipment.

 

Financing Activities

 

For the nine months ended September 30, 2023 and 2022, net cash used in financing activities were $11,586 and $11,091 respectively resulted from the repayment of finance lease.

 

 3 
 

 

Capital Expenditures

 

Our capital expenditures primarily relate to the acquisition of plant and equipment. There were $364 and $8,220 used to purchase the computer and software and office equipment for the nine months periods ended September 30, 2023 and 2022 respectively.

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Contractual Obligations, Commitments and Contingencies

 

We currently have a lease agreement in place with respect to office premises in Malaysia to commence our business operations.

 

Off-balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders as of September 30, 2023.

 

 4 
 

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

 

Additional Information

 

VIE STRUCTURE AND ARRANGEMENTS

 

On June 27, 2016, DSwiss (HK) Limited (“DSHK”) entered into a Management Services Agreement (the “Management Services Agreement I”) which entitles DSHK to substantially entitled to all of the economic benefits of DSwiss Biotech Sdn Bhd (“DSBT”) in consideration of services provided by DSHK to DSBT. Pursuant to the Management Services Agreement I, DSHK has the exclusive right to provide to DSBT management, financial and other services related to the operation of DSBT’s business, and DSBT is required to take all commercially reasonable efforts to permit and facilitate the provision of the services provided by DSHK. As compensation for providing the services, DSHK is entitled to receive a fee from DSBT, upon demand, equal to 100% of the annual net profits of DSBT during the term of the Management Services Agreement I. DSHK may also request ad hoc quarterly payments of the aggregate fee, which payments will be credited against DSBT’s future payment obligations.

 

The Management Services Agreement I also provides DSHK, or its designee, with a right of first refusal to acquire all or any portion of the equity of DSBT upon any proposal by the sole shareholder of DSBT to transfer such equity. In addition, at the sole discretion of DSHK, DSBT is obligated to transfer to DSHK, or its designee, any part or all of the business, personnel, assets and operations of DSBT which may be lawfully conducted, employed, owned or operated by DSHK, including:

 

(a) business opportunities presented to, or available to DSBT may be pursued and contracted for in the name of DSHK rather than DSBT, and at its discretion, DSHK may employ the resources of DSBT to secure such opportunities;

 

(b) any tangible or intangible property of DSBT, any contractual rights, any personnel, and any other items or things of value held by DSBT may be transferred to DSHK at book value;

 

(c) real property, personal or intangible property, personnel, services, equipment, supplies and any other items useful for the conduct of the business may be obtained by DSHK by acquisition, lease, license or otherwise, and made available to DSBT on terms to be determined by agreement between DSHK and DSBT;

 

(d) contracts entered into in the name of DSBT may be transferred to DSHK, or the work under such contracts may be subcontracted, in whole or in part, to DSHK, on terms to be determined by agreement between DSHK and DSBT; and

 

(e) any changes to, or any expansion or contraction of, the business may be carried out in the exercise of the sole discretion of DSHK, and in the name of and at the expense of, DSHK; provided, however, that none of the foregoing may cause or have the effect of terminating (without being substantially replaced under the name of DSHK) or adversely affecting any license, permit or regulatory status of DSBT.

 

In addition, DSHK entered into certain agreements with Jervey Choon, (the “DSBT shareholder”), including

 

(i) a Call Option Agreement allowing DSHK to acquire the shares of DSBT as permitted by Malaysia laws;
   
(ii) a Shareholders’ Voting Rights Proxy Agreement that provides DSHK with the voting rights of the DSBT; and
   
(iii) an Equity Pledge Agreement that pledges the shares in DSBT.

 

This VIE structure provides DSHK, a wholly-owned subsidiary of DSwiss Holding Limited, which is the wholly-owned subsidiary of DSwiss Inc, with control over the operations and benefits of DSBT without having a direct equity ownership in DSBT.

 

 5 
 

 

Item 3 Quantitative and Qualitative Disclosures About Market Risk.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

Item 4 Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures:

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of June 30, 2016. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2023, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2023, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Changes in Internal Control over Financial Reporting:

 

There were no changes in our internal control over financial reporting during the quarter ending September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 6 
 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

 7 
 

 

ITEM 6. Exhibits

 

Exhibit No.   Description
31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
32.1   Section 1350 Certification of principal executive officer *
101.INS   Inline XBRL Instance Document*
101.SCH   Inline XBRL Schema Document*
101.CAL   Inline XBRL Calculation Linkbase Document*
101.DEF   Inline XBRL Definition Linkbase Document*
101.LAB   Inline XBRL Label Linkbase Document*
101.PRE   Inline XBRL Presentation Linkbase Document*
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

 8 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DSWISS, INC.
  (Name of Registrant)
     
Date: November 14, 2023    
     
  By: /s/ Leong Ming Chia
  Title: President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director
    (Principal Executive Officer, Principal Financial Officer)

 

 9